Prediction tracker
This page lists every prediction we have locked and how each one turned out. "Settled" means the event has happened and we have checked the prediction against the real result. Accuracy and calibration (whether our confidence matches reality) can only be judged after events happen. Until then, this page shows what was predicted and what is still waiting. Terms are explained in the glossary.
Locked
24
predictions
Settled
11
events have happened
Awaiting
13
event not yet happened
Outcome accuracy
—
signal return (average gain or loss from our up/down calls)
-12.2%
abstention value (what buying anyway would have returned where we said no edge)
4.3%
range containment (share of results inside our price ranges)
45.5%
our Brier score vs the break-even (from our own price ranges) and the base rate (error size, lower is better)
0.155 / 0.177 / 0.230
Predictions
| Ticker | Catalyst timing | Outcome | Stock | Status | What happened |
|---|---|---|---|---|---|
| VALN s4v2-shigellosis Valneva SE | Mid-2026 placeholder, not a date the company has given | Miss 32%
[20–47]
| $4.60–$5.15 $5.80–$7.00 $5.36+1.2%
modelled estimate
-2.3% to +5.5% compared with the current price, across our 20–47% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| LGVN laromestrocel-hlhs Longeveron Inc | 2026-08-12 → 2026-10-31 confirmed readout window (expected period) | Miss 30%
[20–40]
| $0.22–$0.45 $1.20–$2.20 $0.74+0.6%
modelled estimate
-17.8% to +19.1% compared with the current price, across our 20–40% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — RVEF primary not met (p=0.8336); MACE and clinical composite not significant · -61.6% |
| MNOV mn-001-nafld-hypertriglyceridemia MediciNova, Inc. | 2026-08-26 → 2026-10-31 confirmed readout window (expected period) | Miss 15%
[8–28]
| $1.05–$1.50 $1.60–$2.15 $1.37+2.6%
modelled estimate
-0.5% to +8.5% compared with the current price, across our 8–28% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — neither co-primary was met at Week 24: liver fat by CAP score p=0.2438 and fasting serum triglycerides p=0.113 vs placebo (triglycerides were significant only at Week 4, p=0.015, which is not a co-primary timepoint) · -23.14% |
| ARCT arct-810-otc-deficiency Arcturus Therapeutics Holdings Inc. | 2026-09-01 → 2026-11-30 confirmed readout window (expected period) | Miss 38%
[25–52]
| $6.00–$7.20 $9.50–$13.00 $8.37+5.0%
modelled estimate
-2.6% to +13.1% compared with the current price, across our 25–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — the disclosure the definition settles on (Arcturus 8-K of 2026-09-23, with its presentation and its press release 'Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery Platform') meets clause (a) and fails clause (b). (a) holds: no serious adverse events among the 8 participants (0.3 mg/kg n=4, 0.5 mg/kg n=4) and no hyperammonaemia events of special interest. Two Grade 3 non-serious asymptomatic transaminitis events 'resolved without additional intervention after stopping study drug'; the 2026-08-25 SSIEM poster adds that one participant 'only received 4 doses of investigational medication due to elevated transaminases'. One participant discontinued after a single dose for a non-serious Grade 2 IV infiltration. Neither event is called dose-limiting, no hold or dosing restriction is disclosed, and both dose cohorts completed dosing. (b) fails: Arcturus does not state that ARCT-810 will advance to a registrational or Phase 3 study, and reports no End-of-Phase-2 interaction for it. The regulatory plan is for a different product. After a June 2026 FDA Type C meeting on ARCT-2601 (the OTC mRNA in the next-generation LUNAR 2.0 lipid), Arcturus plans an IND in 4Q 2026, dosing of 3 to 6 patients aged 12 and over in the ongoing ARCT-810 Phase 2 under an amended protocol near year-end, and then a Phase 2/3 paediatric study of ARCT-2601 in H2 2027; the FDA's stated path is to 'Proceed to an adequate and well-controlled pivotal trial if the initial data are favorable'. That is a further Phase 2 step before any pivotal study, for a product other than ARCT-810. Efficacy was reported only as group means of 3 to 4 participants, with no statistics: first-morning fasting ammonia -19% (0.3 mg/kg) and -42% (0.5 mg/kg), and glutamine -17% and -25%, Day 60 against baseline. The ureagenesis (relative urea function) results were not reported. · +1.05% |
| TYRA dabogratinib-ir-nmibc Tyra Biosciences | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Positive 55%
[40–68]
| $14.00–$20.00 $30.00–$46.00 $28.55+5.9%
modelled estimate
-5.8% to +16.0% compared with the current price, across our 40–68% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — pooled 3-month CR 46% (12/26) vs the ≥60% bar; safety clean · -17.75% |
| IRON disc-3405-polycythemia-vera Disc Medicine, Inc. | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Positive 78%
[65–87]
| $67.00–$74.00 $84.00–$91.00 $83.76+5.3%
modelled estimate
+2.6% to +7.3% compared with the current price, across our 65–87% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | positive — 61.5% phlebotomy-free through 26 weeks (Cohort A, n=13), phlebotomies 4.0→0.6 (p<0.0001), well tolerated, advancing · -5.97% |
| EVMN evo756-atopic-dermatitis Evommune, Inc. | 2026-09-01 → 2026-09-30 confirmed readout window (expected period) | Miss 30%
[20–45]
| $8.50–$11.00 $21.00–$30.00 $14.48+1.6%
modelled estimate
-9.5% to +18.2% compared with the current price, across our 20–45% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — primary endpoint (% change in EASI at Week 12) not met at any dose; EVO756 not advanced in AD · -15.58% |
| RARE gtx-102-angelman-syndrome Ultragenyx Pharmaceutical Inc. | 2026-09-01 → 2026-11-10 confirmed readout window (expected period) | Uncertain 50%
[35–65]
| $16.00–$21.00 $34.00–$42.00 $28.25+9.4%
modelled estimate
-1.9% to +20.7% compared with the current price, across our 35–65% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — ASPIRE missed its primary (Bayley-4 cognitive raw score) and key secondary (MDRI) endpoints vs sham · -42.4% |
| CNTB rademikibart-acute-asthma-exacerbation Connect Biopharma Holdings Limited | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Miss 38%
[26–52]
| $0.95–$1.60 $3.60–$6.50 $2.71+16.3%
modelled estimate
-3.2% to +39.0% compared with the current price, across our 26–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | miss — primary 28-day treatment failure not significant (p=0.153); FEV1 key secondary met (p=0.023) · -36% |
| CNTB rademikibart-acute-copd-exacerbation Connect Biopharma Holdings Limited | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Miss 30%
[20–42]
| $1.10–$2.10 $4.00–$7.00 $2.77+8.2%
modelled estimate
-7.0% to +26.5% compared with the current price, across our 20–42% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | positive — the primary endpoint, treatment failure (death from any cause, (re)admission to hospital for COPD, an emergency-department (re)visit or unscheduled visit for worsening COPD, or intensified pharmacologic treatment) within 28 days of randomisation, was reduced by 81% against placebo, p=0.0122 (labelled preliminary): 2 of 78 (2.6%) on rademikibart against 11 of 81 (13.6%) on placebo, failures counted through the Day 28 visit, which the protocol allows at +/-3 days. The company's count of failures within exactly 28 days gives a 77% reduction, p=0.0373. The arm sizes on the efficacy table are the 159 randomised participants (81 and 78); no analysis population is named. Neither the release nor the deck names the test behind the primary's p-value or states its sidedness; the deck's footnote 'Preliminary p-values based on Fisher's Exact' is attached to the hospital/ED-return figure (7/81 against 0/78, p=0.0137). The key secondary, post-bronchodilator FEV1 at Week 1 (Day 7), was not significant, with a 0 mL difference; the release omits it and reports Week 4 instead (+70 mL, p=0.1607). Reported separately from the asthma topline of 2026-09-15. · +0.39% |
| CUE cue-221-csu Cue Biopharma, Inc. | 2026-09-15 → 2026-12-15 confirmed readout window (expected period) | Positive 72%
[58–83]
| $9.00–$16.00 $24.00–$46.00 $28.70+10.0%
modelled estimate
-2.1% to +19.4% compared with the current price, across our 58–83% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | positive — all three CUE-221 dose arms were statistically superior to placebo on the study's primary endpoint (so named in Cue's 8-K and in Shen Lian Biomedical's exchange filing; no registry entry was readable), the proportion of patients with HSS7=0 (no hives over seven days) at Week 12: 4 mg/kg 54% (p<0.005), 2 mg/kg 53% (p<0.005), 1 mg/kg 43% (p<0.05) against placebo 11% (Fisher's exact test, modified intention-to-treat); no treatment-related serious adverse events and no hypersensitivity reactions including anaphylaxis; development continues to a planned Phase 2b/3 in CSU. Omalizumab 300 mg (41%) was not statistically tested against CUE-221 at Week 12. · -20.99% |
| TLSA foralumab-na-spms Tiziana Life Sciences | 2026-09-15 → 2026-11-30 confirmed readout window (expected period) | Miss 35%
[20–52]
| $0.30–$0.55 $1.80–$3.00 $1.12+11.6%
modelled estimate
-18.0% to +45.2% compared with the current price, across our 20–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| DWTX halneuron-cinp Dogwood Therapeutics, Inc. | 2026-10-01 → 2026-12-31 confirmed readout window (expected period) | Miss 38%
[26–49]
| $0.28–$1.28 $3.28–$9.50 $2.91+50.5%
modelled estimate
+15.7% to +82.4% compared with the current price, across our 26–49% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| IVA lanifibranor-mash Inventiva S.A. | 2026-10-01 → 2026-12-31 confirmed readout window (expected period) | Positive 55%
[40–70]
| $1.00–$2.00 $7.00–$13.00 $6.18+30.9%
modelled estimate
+3.8% to +57.8% compared with the current price, across our 40–70% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| GNLX olvi-vec-platinum-resistant-ovarian Genelux Corporation | 2026-10-01 → 2027-04-30 confirmed readout window (expected period) | Uncertain 35%
[20–55]
| $0.45–$1.30 $6.00–$14.00 $4.07+49.6%
modelled estimate
-0.7% to +116.7% compared with the current price, across our 20–55% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| RAPP rap-219-bipolar-mania Rapport Therapeutics, Inc. | 2026-10-01 → 2026-11-30 confirmed readout window (expected period) | Miss 35%
[22–48]
| $37.00–$45.00 $56.00–$68.00 $48.35-1.2%
modelled estimate
-6.8% to +4.4% compared with the current price, across our 22–48% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| CGEM zipalertinib-1l-egfr-ex20ins-nsclc Cullinan Therapeutics, Inc. | 2026-10-01 → 2027-03-31 confirmed readout window (expected period) | Positive 78%
[65–88]
| $13.50–$16.25 $19.50–$24.00 $20.24+12.2%
modelled estimate
+7.3% to +16.1% compared with the current price, across our 65–88% range of probabilities. We cannot tell yet whether it is above or below the current price. | Settled | positive — the top-line release the definition settles on (Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics, 2026-08-12, 'Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer', furnished as Exhibit 99.1 to Cullinan's 8-K) states that REZILIENT3 'met its primary endpoint of progression-free survival (PFS) at a planned interim analysis' and that 'the study demonstrated a statistically significant and clinically meaningful improvement in PFS in the zipalertinib containing arm', against platinum-based chemotherapy alone. The release does not name who assessed PFS. The registry lists the primary outcome as 'Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)', and the Part B comparator as 'pemetrexed and a platinum agent (either carboplatin or cisplatin)'. So the release's 'primary endpoint of PFS' is BICR-assessed PFS against pemetrexed-platinum, and every clause of the definition is met by the top-line itself. Full data (Cullinan 8-K of 2026-09-14; IASLC 2026 World Conference on Lung Cancer, Presidential Symposium, 2026-09-14): at the pre-planned interim efficacy analysis after 122 PFS events, median PFS 14.5 vs 8.5 months, hazard ratio 0.50 (95% CI 0.34-0.73), P=0.00015, in 279 randomised patients (140 vs 139). The September primary documents do not repeat 'BICR'. Three verbatim reports of the presentation (OncLive, ecancer, HMP Global Learning Network; secondary) state that the primary endpoint and the 14.5-month median were by blinded independent central review, and OncLive reports that the interim crossed the prespecified boundary for superiority (primary analysis planned at 162 events; data cutoff 2026-05-29). Secondary results: objective response rate 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months; interim overall survival hazard ratio 0.72 (95% CI 0.42-1.23) at 30% maturity. Grade 3 or higher adverse events 87.1% vs 54.4%, mostly haematologic (58.6% vs 28.7%). · +1.91% |
| IMMP efti-pembrolizumab-soft-tissue-sarcoma Immutep Limited | 2026-10-19 → 2026-10-19 confirmed readout window (expected period) | Positive 85%
[72–92]
| $2.30–$3.00 $3.05–$4.00 $3.39+6.1%
modelled estimate
+2.5% to +8.0% compared with the current price, across our 72–92% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| CMPX tovecimig-biliary-tract-cancer Compass Therapeutics, Inc. | 2026-10-23 → 2026-10-27 confirmed readout window (expected period) | Uncertain 45%
[32–58]
| $0.62–$0.84 $0.87–$1.15 $0.86-0.5%
modelled estimate
-4.7% to +3.8% compared with the current price, across our 32–58% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| ABOS sabirnetug-alzheimers Acumen Pharmaceuticals | 2026-11-15 → 2027-01-31 confirmed readout window (expected period) | Miss 35%
[25–48]
| $0.55–$1.20 $4.50–$11.00 $3.28+43.9%
modelled estimate
+13.8% to +83.1% compared with the current price, across our 25–48% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| IMUX vidofludimus-relapsing-ms Immunic, Inc. | 2026-12-01 → 2027-03-31 confirmed readout window (expected period) | Positive 60%
[50–70]
| $2.40–$3.80 $17.00–$27.00 $14.44+2.4%
modelled estimate
-11.0% to +15.8% compared with the current price, across our 50–70% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| ZNTL azenosertib-cyclin-e1-proc Zentalis Pharmaceuticals | 2027-01-01 → 2027-06-30 confirmed readout window (expected period) | Positive 55%
[42–68]
| $1.00–$2.30 $6.50–$10.00 $5.28+26.9%
modelled estimate
+6.3% to +47.5% compared with the current price, across our 42–68% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| RARE dtx301-otc-deficiency Ultragenyx Pharmaceutical Inc. | 2027-01-01 → 2027-09-30 confirmed readout window (expected period) | Positive 62%
[48–75]
| $22.00–$27.00 $27.00–$33.00 $27.91+4.6%
modelled estimate
+1.8% to +7.3% compared with the current price, across our 48–75% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
| OLMA palazestrant-er-positive-mbc Olema Pharmaceuticals | 2027-01-01 → 2027-06-30 confirmed readout window (expected period) | Uncertain 40%
[30–52]
| $4.50–$8.50 $15.50–$32.00 $13.40+28.5%
modelled estimate
+11.9% to +48.3% compared with the current price, across our 30–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | Awaiting the result | not yet known |
Calibration
Whether our stated confidence matches how often we are right. This fills in as predictions are settled.
Calibration checks whether our stated confidence matches reality. For example, do events we called with medium confidence really happen about as often as that confidence implies?
The chart fills in as predictions are settled. So far, 11 of 24 are settled. The dashed line shows perfect calibration. Points will show the predicted probability against how often it really happened, once there are enough settled predictions to group.